Bioventus Inc
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
BVS$11.02+3.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
Index to Consolidated Financial Statements
| Page | |
|---|---|
| Bioventus Inc. | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID Number 248) | 89 |
| Consolidated Statements of Operations and Comprehensive (Loss) Income | 90 |
| Consolidated Balance Sheets | 91 |
| Consolidated Statements of Changes in Stockholders’ and Members’ Equity | 92 |
| Consolidated Statements of Cash Flows | 93 |
| Notes to the Consolidated Financial Statements | 94 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.